For target-based drug reuse, the ara-CTP and guanosine trip can form multi-hydrogen-bond complexes with POL2B, RPS6 and RPL23A, with low binding energy, suggesting that they may have a better prognosis when used as adjuvant therapy for patients with virus-associated HCC, which is clear from the results. The gene discussed is RPL23A; the disease is hepatocellular carcinoma.